Safety review — page 2
A review of harms, in which the absence of an event in a trial of conventional size is treated as uninformative rather than as reassurance.
Reviews
-
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Orforglipron compared with its comparator?
Moderate16 Jun 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Semaglutide, oral compared with its comparator?
High19 May 2026 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the incidence of adverse events leading to discontinuation with Teduglutide compared with its comparator?
Moderate07 Sep 2026 -
In the population defined for cutaneous wound healing and tissue repair, what is the incidence of adverse events leading to discontinuation with Thymosin beta-4 compared with its comparator?
Low24 Jul 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with CagriSema (cagrilintide with semaglutide) compared with its comparator?
Moderate12 Jun 2025 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the incidence of adverse events leading to discontinuation with CJC-1295 compared with its comparator?
Low17 Apr 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to discontinuation with Dulaglutide compared with its comparator?
High27 Nov 2024 -
In the population defined for cutaneous wound healing and tissue repair, what is the incidence of adverse events leading to discontinuation with GHK-Cu compared with its comparator?
Low02 Dec 2025 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the incidence of adverse events leading to discontinuation with Gonadorelin compared with its comparator?
Moderate23 Jan 2026 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the incidence of adverse events leading to discontinuation with Kisspeptin-10 compared with its comparator?
Moderate26 Jun 2025 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the incidence of adverse events leading to discontinuation with Larazotide acetate compared with its comparator?
Moderate19 Feb 2026 -
In the population defined for adjunctive therapy in type 1 diabetes, what is the incidence of adverse events leading to discontinuation with Liraglutide compared with its comparator?
Moderate07 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Liraglutide compared with its comparator?
High03 Mar 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Maridebart cafraglutide compared with its comparator?
Low21 Jan 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Petrelintide compared with its comparator?
Low11 Feb 2026 -
In the population defined for hypoactive sexual desire and erectile dysfunction, what is the incidence of adverse events leading to discontinuation with PT-141 (bremelanotide) compared with its comparator?
Moderate05 Jun 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Retatrutide compared with its comparator?
Moderate12 Jun 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to discontinuation with Semaglutide compared with its comparator?
High14 Apr 2026 -
In the population defined for heart failure with preserved ejection fraction and obesity, what is the incidence of adverse events leading to discontinuation with Semaglutide compared with its comparator?
Moderate23 Jan 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to discontinuation with Semaglutide, oral compared with its comparator?
Moderate02 Mar 2026
page 2 of 3